Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Eli Lilly & Co. is the first pharmaceutical stock to hit a $1 trillion valuation, with its stock’s rise driven by a methodical approach to capturing an obesity-drug market that didn’t exist five years ...

The booming market for weight-loss drugs has propelled Eli Lilly LLY-0.41%decrease; red down pointing triangle to become the first pharmaceutical company to hit $1 trillion in market capitalization, ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Silicon Valley’s giants crowd the list of the world’s most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of $1 trillion on Friday, ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies to provide direct access to their popular obesity meds. Thursday morning, ...

Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using artificial intelligence to discover new drugs. The Indianapolis Big Pharma will combine Insilico’s Pharma ...

Eli Lilly (LLY) has reached a research and licensing agreement worth up to $1.2B with SanegeneBio to develop and commercialize RNAi therapeutics for metabolic diseases, the Boston, Massachusetts-based ...

Early results showed that patients lost up to 20.1% of their body weight. Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 ...

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher. The U.S. weight loss drug giant reported ...